DSpace Repository

Persistent hypercalcemia is a significant risk factor for graft dysfunction in renal transplantation recipients

Show simple item record

dc.creator Haberal, M
dc.creator Usluogullan, C
dc.creator Akgul, A
dc.creator Afsar, Barış
dc.creator Ozdemir, FN
dc.creator Akcay, A
dc.date 2006-03-01T01:00:00Z
dc.date.accessioned 2021-12-03T12:05:40Z
dc.date.available 2021-12-03T12:05:40Z
dc.identifier fd5451cc-0945-4320-8e7b-77dec5f00185
dc.identifier 10.1016/j.transproceed.2005.12.065
dc.identifier https://avesis.sdu.edu.tr/publication/details/fd5451cc-0945-4320-8e7b-77dec5f00185/oai
dc.identifier.uri http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/96027
dc.description Hypercalcemia is a common problem in renal transplant recipients, although in most cases, spontaneous resolution occurs within 1 year after renal transplantation. This condition may persist in some patients producing effects on renal function which are not well understood. In this study, we sought to analyze the effect of persistent hypercalcemia in the posttransplantation period on the function of renal transplants. A total of 121 recipients (31 women, 90 men; mean age, 34.1 +/- 9.9 years) underwent renal transplantation between 1999 and 2002. All patients underwent prospective evaluation of their serum calcium levels at 6-month intervals. A sustained corrected mean serum calcium level higher than 10.2 mg/dL was defined as "persistent hypercaicemia." Patients who had a gradual increase in their serum creatinine levels to > 2 mg/dL or a 50% rise above the baseline were considered to display chronic allograft dysfunction (CAD). Among 121 recipients, 52 patients (43%) developed CAD and 37 patients (30.6%) had persistent hypercalcemia. Among the CAD patients, 22 suffered persistent hypercalcemia, while the other 15 patients were without CAD, a difference that was statistically significant (42.3% vs 21.7%, P = .01). The mean calcium levels were lower among patients without than with CAD, a difference that did not reach statistical significance (9.9 +/- 0.4 mg/dL vs 1.0.1 +/- 0.6 mg/dL, P = .1). In conclusion, persistent hypercalcemia in the posttransplantation period may significantly contribute to the development of chronic allograft nephropathy.
dc.language eng
dc.rights info:eu-repo/semantics/closedAccess
dc.title Persistent hypercalcemia is a significant risk factor for graft dysfunction in renal transplantation recipients
dc.type info:eu-repo/semantics/article


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account